Chimeric peptide-based radiopharmaceuticals for glioblastoma imaging and therapy by targeting mHsp70 and enhancing BBB penetration.
Overview
- Chair of Medicinal and Bioinorganic Chemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Lichtenbergstrasse 4, 85748 Garching bei München, Germany
- Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, CTN, LRS, Estrada Nacional 10, 2695-066 Bobadela, Portugal
- Department of Nuclear Medicine, TUM University Hospital, Central Institute for Translational Cancer Research (TranslaTUM), School of Medicine and Health, Technical University of Munich, 81675 Munich, Germany
- Departamento de Engenharia e Ciências Nucleares, Instituto Superior Técnico, Universidade de Lisboa, LRS, Estrada Nacional 10, 2695-066 Bobadela, Portugal
- Fundação GIMM – Gulbenkian Institute for Molecular Medicine, Avenida Professor Egas Moniz, Lisboa, 1649–028, Portugal
- Instituto de Bioquímica, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, Lisboa, 1649–028, Portugal
Abstract
Glioblastoma (GBM) is the most aggressive form of malignant brain cancer. Here, we synthesized two chimeric peptide-based radiopharmaceuticals (Comb-1 and Comb-2) targeted to the membrane-bound form of heat shock protein 70 (mHsp70), which is overexpressed in GBM tissues, for future theranostic applications. The design concept features a DOTA chelator for coordination to different radiometals tethered directly or via a PEG linker to a chimeric peptide. The latter combines the Hsp70-targeting ability of the TPP sequence with the blood–brain barrier (BBB) penetration of another 7-amino acid sequence (d-PepH3) derived from the dengue virus capsid protein (DEN2C). The two compounds were successfully radiolabelled with gallium-67, suitable for single photon emission computed tomography (SPECT) imaging, or with lutetium-177 for β− therapy. Furthermore, the in vitro properties of the ligand, including lipophilicity (log D7.4), human serum albumin (HSA) binding, and stability in human serum were evaluated. The presence of the TPP sequence affected the half-life of the combinatorial peptides. Cytometry assays performed with a fluorescent analogue of Comb-2 confirmed the binding to mHsp70-expressing U87-MG cells. In an in vitro model, all tracers demonstrated the ability to cross the BBB, indicating that conjugation of the mHsp70-targeting peptide to the PepH3 sequence did not impair its translocating properties. Biodistribution experiments with 67Ga-labeled compounds were performed in naive female CD1 mice and showed brain uptake at 2 min p.i., as well as renal excretion. For the best performing compound [67Ga]Ga-Comb-2 (0.60 ± 0.17% IA g−1 (injected activity per gram)), the biodistribution experiment was also performed with perfusion of the organs after sacrifice, and the results showed retention of radioactivity in the brain (0.14 ± 0.05% IA g−1). Further metabolic studies in murine urine and blood were performed after biodistribution, confirming the stability of the chimeric tracers.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- zenodo:20183561, at Zenodo; found in “Data availability”
Data availability
Original cytometry data files have been provided on Zenodo, DOI: https://
The data supporting this article, including abbreviations, additional experimental procedures, characterization data, additional figures and tables, chromatograms, and spectra, are included in the supplementary information (SI). Supplementary information: details on the synthesis and characterization of peptide-based radiotracers, as well as RP-HPLC chromatograms and (HR-) ESI-MS spectra of quality controls and radioactive labeling; and data on stability studies, cytometry analysis, in silico prediction of BBB translocation, biodistribution, and metabolic studies. See DOI: https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 12 authors, 4 funders, 67 references.
Cite
This paper
Schuderer, F., Silva, R. D. M., Pinto, C. I. G., Koller, L., Stangl, S., Gano, L., Cavaco, M., Castanho, M. A. R., Mendes, F., Kossatz, S., Correia, J. D. G., & Casini, A. (2026). Chimeric peptide-based radiopharmaceuticals for glioblastoma imaging and therapy by targeting mHsp70 and enhancing BBB penetration. Chemical science, 17(29), 14222-14236. https://
BibTeX
@article{schuderer2026ch
author = {Schuderer, Franziska and Silva, Rúben D M and Pinto, Catarina I G and Koller, Lena and Stangl, Stefan and Gano, Lurdes and Cavaco, Marco and Castanho, Miguel A R and Mendes, Filipa and Kossatz, Susanne and Correia, João D G and Casini, Angela},
title = {{Chimeric peptide-based radiopharmaceuticals for glioblastoma imaging and therapy by targeting mHsp70 and enhancing BBB penetration}},
journal = {Chemical science},
year = {2026},
month = jun,
volume = {17},
number = {29},
pages = {14222--14236},
publisher = {Royal Society of Chemistry},
issn = {2041-6520},
doi = {10.1039/
url = {https://
pmid = {42306550},
pmcid = {PMC13267484}
}
RIS
TY - JOUR
AU - Schuderer, Franziska
AU - Silva, Rúben D M
AU - Pinto, Catarina I G
AU - Koller, Lena
AU - Stangl, Stefan
AU - Gano, Lurdes
AU - Cavaco, Marco
AU - Castanho, Miguel A R
AU - Mendes, Filipa
AU - Kossatz, Susanne
AU - Correia, João D G
AU - Casini, Angela
TI - Chimeric peptide-based radiopharmaceuticals for glioblastoma imaging and therapy by targeting mHsp70 and enhancing BBB penetration
T2 - Chemical science
J2 - Chem Sci
PY - 2026
DA - 2026/
VL - 17
IS - 29
SP - 14222
EP - 14236
SN - 2041-6520
PB - Royal Society of Chemistry
DO - 10.1039/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1039/
"type": "article-journal",
"title": "Chimeric peptide-based radiopharmaceuticals for glioblastoma imaging and therapy by targeting mHsp70 and enhancing BBB penetration",
"container-title": "Chemical science",
"author": [
{
"family": "Schuderer",
"given": "Franziska"
},
{
"family": "Silva",
"given": "Rúben D M"
},
{
"family": "Pinto",
"given": "Catarina I G"
},
{
"family": "Koller",
"given": "Lena"
},
{
"family": "Stangl",
"given": "Stefan"
},
{
"family": "Gano",
"given": "Lurdes"
},
{
"family": "Cavaco",
"given": "Marco"
},
{
"family": "Castanho",
"given": "Miguel A R"
},
{
"family": "Mendes",
"given": "Filipa"
},
{
"family": "Kossatz",
"given": "Susanne"
},
{
"family": "Correia",
"given": "João D G"
},
{
"family": "Casini",
"given": "Angela"
}
],
"container-title-short":
"volume": "17",
"issue": "29",
"page": "14222-14236",
"DOI": "10.1039/
"PMID": "42306550",
"PMCID": "PMC13267484",
"ISSN": "2041-6520",
"publisher": "Royal Society of Chemistry",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
6,
3
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1021/acs.jmedchem.5c01073
- N-Heterocyclic Carbenes as Ligands to <sup>198</
sup>Au(I)-Radiolabeled Compounds: A New Platform for Radiopharmaceutical Design. Journal: Journal of medicinal chemistryIn common: 4 references, 3 authors - [2] doi:10.1002/advs.202517834
- Data-Driven Feedback Identifies Focused Ultrasound Exposure Regimens for Improved Nanotheranostic Targeting of the Brain.Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)In common: other condition, mouse, 3 references
- [3] doi:10.1038/s41435-025-00327-5
- Comprehensive analysis of heat shock proteins in glioma revealed the association with glioma-associated myeloid cells.Journal: Genes and immunityIn common: other condition, 2 references
- [4] doi:10.1038/s41565-025-01867-7
- Systemic HER3 ligand-mimicking nanobioparticles enter the brain and reduce intracranial tumour growth.Journal: Nature nanotechnologyIn common: other condition, mouse, 2 references
- [5] doi:10.1002/advs.202523984 [code]
- INB&
lt;sup& gt;3& lt;/ sup& gt;P: A Multi-Modal and Interpretable Co-Attention Framework Integrating Property-Aware Explanations and Memory-Bank Contrastive Fusion for Blood-Brain Barrier Penetrating Peptide Discovery. Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)In common: 2 references - [6] doi:10.1016/j.celrep.2022.110839
- Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors.Journal: Cell reportsIn common: clinical / translational, other condition, 2 references
- [7] doi:10.1126/sciadv.adr6940
- Immune cell infiltration into brain tumor microenvironment is mediated by Rab27-regulated vascular wall integrity.Journal: Science advancesIn common: other condition, mouse, 2 references
- [8] doi:10.1021/acs.jmedchem.1c01946
- Glioblastoma: Current Status, Emerging Targets, and Recent Advances.Journal: Journal of medicinal chemistryIn common: other condition, 2 references
- [9] doi:10.3390/ph18020217 [code]
- Computational Modeling of Pharmaceuticals with an Emphasis on Crossing the Blood-Brain Barrier.Journal: Pharmaceuticals (Basel, Switzerland)In common: 2 references
- [10] doi:10.1186/s12915-025-02419-0 [code]
- DeepB&
lt;sup& gt;3& lt;/ sup& gt;Pred: blood-brain barrier peptide predictor using stacked BiGRU model with novel features. Journal: BMC biologyIn common: 2 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
